Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal Cells

Fetal growth restriction (FGR) is a major complication of prenatal ischemic/hypoxic exposure and affects 5%–10% of pregnancies. It causes various disorders, including neurodevelopmental disabilities due to chronic hypoxia, circulatory failure, and malnutrition via the placenta, and there is no estab...

Full description

Bibliographic Details
Main Authors: Yuma Kitase, Yoshiaki Sato, Sakiko Arai, Atsuto Onoda, Kazuto Ueda, Shoji Go, Haruka Mimatsu, Mahboba Jabary, Toshihiko Suzuki, Miharu Ito, Akiko Saito, Akihiro Hirakawa, Takeo Mukai, Tokiko Nagamura-Inoue, Yoshiyuki Takahashi, Masahiro Tsuji, Masahiro Hayakawa
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Cellular Neuroscience
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fncel.2020.00212/full
id doaj-0819522d34f34b02b8c0f8d0568b9e60
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Yuma Kitase
Yuma Kitase
Yoshiaki Sato
Sakiko Arai
Sakiko Arai
Atsuto Onoda
Atsuto Onoda
Kazuto Ueda
Shoji Go
Haruka Mimatsu
Haruka Mimatsu
Mahboba Jabary
Mahboba Jabary
Toshihiko Suzuki
Miharu Ito
Akiko Saito
Akihiro Hirakawa
Takeo Mukai
Tokiko Nagamura-Inoue
Yoshiyuki Takahashi
Masahiro Tsuji
Masahiro Hayakawa
spellingShingle Yuma Kitase
Yuma Kitase
Yoshiaki Sato
Sakiko Arai
Sakiko Arai
Atsuto Onoda
Atsuto Onoda
Kazuto Ueda
Shoji Go
Haruka Mimatsu
Haruka Mimatsu
Mahboba Jabary
Mahboba Jabary
Toshihiko Suzuki
Miharu Ito
Akiko Saito
Akihiro Hirakawa
Takeo Mukai
Tokiko Nagamura-Inoue
Yoshiyuki Takahashi
Masahiro Tsuji
Masahiro Hayakawa
Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal Cells
Frontiers in Cellular Neuroscience
umbilical cord-derived mesenchymal stromal cells
fetal growth restriction
mesenchymal stem cell
neurodevelopment
stem cells
author_facet Yuma Kitase
Yuma Kitase
Yoshiaki Sato
Sakiko Arai
Sakiko Arai
Atsuto Onoda
Atsuto Onoda
Kazuto Ueda
Shoji Go
Haruka Mimatsu
Haruka Mimatsu
Mahboba Jabary
Mahboba Jabary
Toshihiko Suzuki
Miharu Ito
Akiko Saito
Akihiro Hirakawa
Takeo Mukai
Tokiko Nagamura-Inoue
Yoshiyuki Takahashi
Masahiro Tsuji
Masahiro Hayakawa
author_sort Yuma Kitase
title Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal Cells
title_short Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal Cells
title_full Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal Cells
title_fullStr Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal Cells
title_full_unstemmed Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal Cells
title_sort establishment of a novel fetal growth restriction model and development of a stem-cell therapy using umbilical cord-derived mesenchymal stromal cells
publisher Frontiers Media S.A.
series Frontiers in Cellular Neuroscience
issn 1662-5102
publishDate 2020-07-01
description Fetal growth restriction (FGR) is a major complication of prenatal ischemic/hypoxic exposure and affects 5%–10% of pregnancies. It causes various disorders, including neurodevelopmental disabilities due to chronic hypoxia, circulatory failure, and malnutrition via the placenta, and there is no established treatment. Therefore, the development of treatments is an urgent task. We aimed to develop a new FGR rat model with a gradual restrictive load of uterus/placental blood flow and to evaluate the treatment effect of the administration of umbilical cord-derived mesenchymal stromal cells (UC-MSCs). To create the FGR rat model, we used ameroid constrictors that had titanium on the outer wall and were composed of C-shaped casein with a notch and center hole inside that gradually narrowed upon absorbing water. The ameroid constrictors were attached to bilateral ovarian/uterine arteries on the 17th day of pregnancy to induce chronic mild ischemia, which led to FGR with over 20% bodyweight reduction. After the intravenous administration of 1 × 105 UC-MSCs, we confirmed a significant improvement in the UC-MSC group in a negative geotaxis test at 1 week after birth and a rotarod treadmill test at 5 months old. In the immunobiological evaluation, the total number of neurons counted via the stereological counting method was significantly higher in the UC-MSC group than in the vehicle-treated group. These results indicate that the UC-MSCs exerted a treatment effect for neurological impairment in the FGR rats.
topic umbilical cord-derived mesenchymal stromal cells
fetal growth restriction
mesenchymal stem cell
neurodevelopment
stem cells
url https://www.frontiersin.org/article/10.3389/fncel.2020.00212/full
work_keys_str_mv AT yumakitase establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
AT yumakitase establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
AT yoshiakisato establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
AT sakikoarai establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
AT sakikoarai establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
AT atsutoonoda establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
AT atsutoonoda establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
AT kazutoueda establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
AT shojigo establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
AT harukamimatsu establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
AT harukamimatsu establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
AT mahbobajabary establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
AT mahbobajabary establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
AT toshihikosuzuki establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
AT miharuito establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
AT akikosaito establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
AT akihirohirakawa establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
AT takeomukai establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
AT tokikonagamurainoue establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
AT yoshiyukitakahashi establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
AT masahirotsuji establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
AT masahirohayakawa establishmentofanovelfetalgrowthrestrictionmodelanddevelopmentofastemcelltherapyusingumbilicalcordderivedmesenchymalstromalcells
_version_ 1724583198526013440
spelling doaj-0819522d34f34b02b8c0f8d0568b9e602020-11-25T03:28:35ZengFrontiers Media S.A.Frontiers in Cellular Neuroscience1662-51022020-07-011410.3389/fncel.2020.00212524508Establishment of a Novel Fetal Growth Restriction Model and Development of a Stem-Cell Therapy Using Umbilical Cord-Derived Mesenchymal Stromal CellsYuma Kitase0Yuma Kitase1Yoshiaki Sato2Sakiko Arai3Sakiko Arai4Atsuto Onoda5Atsuto Onoda6Kazuto Ueda7Shoji Go8Haruka Mimatsu9Haruka Mimatsu10Mahboba Jabary11Mahboba Jabary12Toshihiko Suzuki13Miharu Ito14Akiko Saito15Akihiro Hirakawa16Takeo Mukai17Tokiko Nagamura-Inoue18Yoshiyuki Takahashi19Masahiro Tsuji20Masahiro Hayakawa21Division of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanFaculty of Pharmaceutical Sciences, Sanyo-Onoda City University, Yamaguchi, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanClinical Research Center, Division of Biostatistics and Data Science, Medical and Dental University, Tokyo, JapanDepartment of Cell Processing and Transfusion, Institute of Medical Science, University of Tokyo, Tokyo, JapanDepartment of Cell Processing and Transfusion, Institute of Medical Science, University of Tokyo, Tokyo, JapanDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, JapanDepartment of Food and Nutrition, Faculty of Home Economics, Kyoto Women’s University, Kyoto, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanFetal growth restriction (FGR) is a major complication of prenatal ischemic/hypoxic exposure and affects 5%–10% of pregnancies. It causes various disorders, including neurodevelopmental disabilities due to chronic hypoxia, circulatory failure, and malnutrition via the placenta, and there is no established treatment. Therefore, the development of treatments is an urgent task. We aimed to develop a new FGR rat model with a gradual restrictive load of uterus/placental blood flow and to evaluate the treatment effect of the administration of umbilical cord-derived mesenchymal stromal cells (UC-MSCs). To create the FGR rat model, we used ameroid constrictors that had titanium on the outer wall and were composed of C-shaped casein with a notch and center hole inside that gradually narrowed upon absorbing water. The ameroid constrictors were attached to bilateral ovarian/uterine arteries on the 17th day of pregnancy to induce chronic mild ischemia, which led to FGR with over 20% bodyweight reduction. After the intravenous administration of 1 × 105 UC-MSCs, we confirmed a significant improvement in the UC-MSC group in a negative geotaxis test at 1 week after birth and a rotarod treadmill test at 5 months old. In the immunobiological evaluation, the total number of neurons counted via the stereological counting method was significantly higher in the UC-MSC group than in the vehicle-treated group. These results indicate that the UC-MSCs exerted a treatment effect for neurological impairment in the FGR rats.https://www.frontiersin.org/article/10.3389/fncel.2020.00212/fullumbilical cord-derived mesenchymal stromal cellsfetal growth restrictionmesenchymal stem cellneurodevelopmentstem cells